Endocrinology, Vol 107, 884-891, Copyright © 1980 by Endocrine Society

ARTICLES

17 alpha-Estradiol is a biologically active estrogen in human breast cancer cells in tissue culture

DP Edwards and WL McGuire

The biological effects of 17 alpha-estradiol (17 alpha-E) and its interaction with estrogen receptors were studied in the MCF-7 human breast cancer cell line. Competition for [3H]17 beta-estradiol ([3H]17 beta-E) binding shows that 17 alpha-E binds to receptor with high affinity and has a dissociation constant (Kd) estimated to be 0.7 nM. Upon binding with 17 alpha-E, the cytosol receptor is translocated to the nucleus and is then rapidly depleted or processed in the same manner as the 17 beta-E-receptor complex. The nuclear 17 alpha-E- receptor complex was determined to be biologically active by its ability to stimulate an increase in the progesterone receptor content and to reverse antiestrogen inhibition of cellular proliferation and DNA polymerase activity. The estrogenic potency of 17 alpha-E, estimated from the dose-response curves as the median effective dose in stimulating progesterone receptor content and in reversing antiestrogen inhibition, is about one tenth the potency of 17 beta-E. Competition curves show that 17 alpha-E binds to the cytosol estrogen receptor with about one third the affinity of 17 beta-E, so the correlation between relative binding affinity and biological potency is not perfect. The correlation, however, is reasonably good compared with that in animal studies, in which 17 alpha-E displays negligible biological activity. Gas chromatography and mass spectrometry rule out the possibility that the observed estrogenic activity of 17 alpha-E was due to contamination of the preparation with the more active 17 beta-E. The enhanced estrogenic potency of 17 alpha-E in MCF-7 cells raises the question of whether the stereospecificity and, thus, the sensitivity of the estrogen receptors in breast cancer cells may be different than those in normal target tissues. Enhanced estrogenic activity may also be due simply to the nature of the tissue culture system, which allows continuous exposure of the cells to hormone; a condition which may not be achieved in some animal studies.

This article has been cited by other articles:

				J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, September 29, 2006; 313(5795): 1929 - 1935. [Abstract] [Full Text] [PDF]

				C. D. Toran-Allerand, A. A. Tinnikov, R. J. Singh, and I. S. Nethrapalli 17{alpha}-Estradiol: A Brain-Active Estrogen? Endocrinology, September 1, 2005; 146(9): 3843 - 3850. [Abstract] [Full Text] [PDF]

				Y.-S. Zhu, L.-Q. Cai, Y. Huang, J. Fish, L. Wang, Z.-K. Zhang, and J. L. Imperato-McGinley Receptor Isoform and Ligand-Specific Modulation of Dihydrotestosterone-Induced Prostate Specific Antigen Gene Expression and Prostate Tumor Cell Growth by Estrogens J Androl, July 1, 2005; 26(4): 500 - 508. [Abstract] [Full Text] [PDF]

				J. N. Holloway, S. Murthy, and D. El-Ashry A Cytoplasmic Substrate of Mitogen-Activated Protein Kinase Is Responsible for Estrogen Receptor-{alpha} Down-Regulation in Breast Cancer Cells: The Role of Nuclear Factor-{kappa}B Mol. Endocrinol., June 1, 2004; 18(6): 1396 - 1410. [Abstract] [Full Text] [PDF]

				M. T. Tilli, M. S. Frech, M. E. Steed, K. S. Hruska, M. D. Johnson, J. A. Flaws, and P. A. Furth Introduction of Estrogen Receptor-{alpha} into the tTA/TAg Conditional Mouse Model Precipitates the Development of Estrogen-Responsive Mammary Adenocarcinoma Am. J. Pathol., November 1, 2003; 163(5): 1713 - 1719. [Abstract] [Full Text] [PDF]

				A. S. Oh, L. A. Lorant, J. N. Holloway, D. L. Miller, F. G. Kern, and D. El-Ashry Hyperactivation of MAPK Induces Loss of ER{alpha} Expression in Breast Cancer Cells Mol. Endocrinol., August 1, 2001; 15(8): 1344 - 1359. [Abstract] [Full Text] [PDF]